Oxstones Investment Club™Central European countries, specifically Poland, Hungary, the Czech Republic, Romania, Slovakia and Bulgaria, have become increasingly popular as locations for clinical trials in major therapeutic categories in recent years. As patents for high profile drugs near their expiration dates, time pressure on companies to advance new products through the stages of clinical are steadily increasing. The prevailing conditions, along with lower cost structures and a larger group of willing participants, are attracting new sponsors and CROs to the region, resulting in recent market growth and an outlook that predicts continued expansion over the next two years.
PMR has prepared a new market guide, Clinical trials in Central Europe 2012, Development forecasts for 2012-2014, in response to the need for professionals to keep up with increased activity and changing conditions in this volatile marketplace.
“In the area of clinical trials, the Central European region provides unique advantages to international pharmaceutical concerns: the associated costs of trials remain relatively low, it is easier to find appropriate candidates to participate in a clinical trial, as candidates are more interested in participation due to lack of money and limited reimbursement. The region analysed still participates in a centralised healthcare system, which means that its countries contain large hospitals that specialise in oncology, cardiology and rheumatology, which rank among the most popular therapeutic categories for clinical trials. Worthy of note, however, are the drawbacks and barriers described by the report as they represent crucial knowledge for any company conducting (or intending to commence) clinical trials in the six countries analysed in the publication.”
In order to locate and capitalize on new opportunities, you need direct access to the latest news, sharpest analysis, most reliable statistics and knowledgeable trends forecasting available. Read, Clinical trials in Central Europe 2012, Development forecasts for 2012-2014 today, and refer to this new report from PMR on a regular basis as you monitor market expansion and contemplate new business strategies.
It offers data on recent, current and forecast trials, an extensive look at the market’s most active players, regulatory environments in each of the six covered countries, and much more.
The report describes overall market size in terms of the number of trials, and breaks down the data by each individual country. It provides astute analysis of specific trends that attract large pharmaceutical companies to the region in search of locations for new trials, such as regulatory conditions and average registration times. A comparative analysis of the environments that professionals work within to launch a new trial and conduct it through completion reveals the best and worst choices among covered countries for successful, efficient drug trials both currently and in the period to 2014.
While preparing Clinical trials in Central Europe 2012, Development forecasts for 2012-2014, PMR’s expert analysts have consulted their most reliable sources and created a truly unique market guide that deals with the complexities intrinsic to both the current status and future progression of this dynamic marketplace.
For more information on the report please contact:
Marketing Department:
tel. /48/ 12 618 90 00
e-mail: marketing@pmrcorporate.com
Tags: big pharma, cardiology and rheumatology, centralised healthcare system, clinical trials, Clinical trials in Central Europe, CROs, drug patent expirations, eastern europe popular as locations for clinical trials, Hungary, large hospitals that specialise in oncology, large pharmaceutical companies in search of locations for new trials, lower cost structures, poland, romania, Slovakia and Bulgaria, the Czech Republic, time pressure on companies to advance new products through the stages of clinical are steadily increasing